Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LJ1B
|
|||
| Former ID |
DCL000955
|
|||
| Drug Name |
Reparixin
|
|||
| Synonyms |
reparixin; repertaxin; 266359-83-5; UNII-U604E1NB3K; CHEMBL191413; U604E1NB3K; DF 1681Y; (R)-2-(4-isobutylphenyl)-N-(methylsulfonyl)propanamide; Reparixin [USAN:INN]; (2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide; (2R)-2-(4-(2-Methylpropyl)phenyl)-N-methylsulfonylpropanamide; 2-(4-isobutylphenyl)propionylmethanesulfonamide; Reparixin (USAN/INN); DSSTox_RID_81678; DSSTox_CID_26509; DSSTox_GSID_46509; ZINC8717; SCHEMBL1884299; GTPL8498; DTXSID6046509; EX-A2461; DF-1681Y; BCP10635; Tox21_112272; BDBM50169045; Repertaxin; Reparixin [INN]; Reparixin (INN/USAN); (R)-2-(4-isobutylphenyl)propionylmethanesulfonamide; RAPARIXIN
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pancreatic islet transplantation failure [ICD-11: NE84] | Phase 3 | [1] | |
| Graft rejection in heart transplantation [ICD-11: NE84] | Phase 2 | [2], [3] | ||
| Ischemia-reperfusion injury [ICD-11: DB98.B; ICD-10: K76.8] | Phase 2 | [2], [3] | ||
| lung transplantation [ICD-11: PK80.20] | Phase 2 | [2], [3] | ||
| Company |
Dompe s.p.a.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H21NO3S
|
|||
| Canonical SMILES |
CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C
|
|||
| InChI |
1S/C14H21NO3S/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-19(4,17)18/h5-8,10-11H,9H2,1-4H3,(H,15,16)/t11-/m1/s1
|
|||
| InChIKey |
KQDRVXQXKZXMHP-LLVKDONJSA-N
|
|||
| CAS Number |
CAS 266359-83-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-X-C chemokine receptor type 1 (CXCR1) | Target Info | Modulator | [4], [5] |
| C-X-C chemokine receptor type 2 (CXCR2) | Target Info | Modulator | [4], [5] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Chemokine signaling pathway | ||||
| Endocytosis | ||||
| Epithelial cell signaling in Helicobacter pylori infection | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Interleukin signaling pathway | ||||
| Pathway Interaction Database | IL8- and CXCR2-mediated signaling events | |||
| IL8- and CXCR1-mediated signaling events | ||||
| Reactome | Chemokine receptors bind chemokines | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| Differentiation Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8498). | |||
| REF 3 | New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. | |||
| REF 4 | 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. | |||
| REF 5 | Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontane... Biol Pharm Bull. 2011;34(1):120-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.